Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
LYNX study of subcu dara + car/dex (D-Kd) vs. Kd in pts with relapsed/refractory myeloma who received previous daratumumab shows no significant differences in ≥VGPR rates between treatment groups. Is repeating Dara dead?”
Title: Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study
Authors: Nizar J. Bahlis, Jeffrey Zonder, Lionel Karlin, Torben Plesner, Laura Paris, Tomasz Wrobel, Vania Hungria, Britta Besemer, Edvan Crusoe, Trine Silkjaer, Aurore Perrot, Philippe Moreau, Ka Lung Wu, Sosana Delimpasi, Meletios A. Dimopoulos, Mark-David Levin, Silvia Mangiacavalli, Ivo Nnane, Yu Jin Kim, Maria Krevvata, Linlin Sha, Susan Wroblewski, Alba Tuozzo, Robin Carson, and Thierry Facon
You can read the Full Article in Leukemia and Lymphoma.
You can find more posts featuring Robert Orlowski on OncoDaily.
